Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinical and Biomedical Research |
Texto Completo: | https://seer.ufrgs.br/index.php/hcpa/article/view/77856 |
Resumo: | Introduction: Metabolism of iron is altered in patients infected with chronically Hepatitis C. The aim of this study is to compare compare the hepcidin levels in between individuais chronically infected with HCV and uninfected individuals. The aim of this study is to compare the hepcidin serum levels between individuals chronically infected with HCV and uninfected individuals.Methods: A cross-sectional study evaluating hepcidin serum levels of mono-infected HCV (n=29), naive, non-diabetic, non-cirrhotic and non-obese patients by means of ELISA, compared to uninfected patients (n=9) with the same characteristics. The degree of liver fibrosis, according to the METAVIR scale on liver biopsies, the lipid profile, the resistance insulin level, as calculated on HOMA-IR (homeostatic model assessment for insulin resistance), the interleukin-6 (IL-6) and the ferritin serum levels were also measured.Results: The levels of hepcidin were significantly lower in HCV patients compared to controls (8.4 pg/mL (±4.94) vs. 19.51 pg/mL (±5.51)) with p<0.001. The levels of ferritin and hepcidin did not show any relation. There was no difference between hepcidin levels in relation to viral genotype, viral load, IL-6 and degrees of fibrosis within HCV infected individuals.Conclusion: It is possible that hepatic iron overload in this population is explained by suppressed levels of hepcidin in patients with HCV.Keywords: Hepcidin; HCV; interleukin-6 (IL-6); mono-infected |
id |
UFRGS-20_99ee9c63b8ea0c7cbd24035e32757988 |
---|---|
oai_identifier_str |
oai:seer.ufrgs.br:article/77856 |
network_acronym_str |
UFRGS-20 |
network_name_str |
Clinical and Biomedical Research |
repository_id_str |
|
spelling |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individualsHepcidinHCVinterleukin-6 (IL-6)mono-infectedHepatologyIntroduction: Metabolism of iron is altered in patients infected with chronically Hepatitis C. The aim of this study is to compare compare the hepcidin levels in between individuais chronically infected with HCV and uninfected individuals. The aim of this study is to compare the hepcidin serum levels between individuals chronically infected with HCV and uninfected individuals.Methods: A cross-sectional study evaluating hepcidin serum levels of mono-infected HCV (n=29), naive, non-diabetic, non-cirrhotic and non-obese patients by means of ELISA, compared to uninfected patients (n=9) with the same characteristics. The degree of liver fibrosis, according to the METAVIR scale on liver biopsies, the lipid profile, the resistance insulin level, as calculated on HOMA-IR (homeostatic model assessment for insulin resistance), the interleukin-6 (IL-6) and the ferritin serum levels were also measured.Results: The levels of hepcidin were significantly lower in HCV patients compared to controls (8.4 pg/mL (±4.94) vs. 19.51 pg/mL (±5.51)) with p<0.001. The levels of ferritin and hepcidin did not show any relation. There was no difference between hepcidin levels in relation to viral genotype, viral load, IL-6 and degrees of fibrosis within HCV infected individuals.Conclusion: It is possible that hepatic iron overload in this population is explained by suppressed levels of hepcidin in patients with HCV.Keywords: Hepcidin; HCV; interleukin-6 (IL-6); mono-infectedHCPA/FAMED/UFRGS2018-07-19info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed ArticleAvaliado por Paresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/77856Clinical & Biomedical Research; Vol. 38 No. 2 (2018): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 38 n. 2 (2018): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSenghttps://seer.ufrgs.br/index.php/hcpa/article/view/77856/pdfCopyright (c) 2018 Ari Ben Hur Stefani Leao, Maria da Graça Ferronato, Carlos Kupski, Fernando Comunello Schacher, Denise Machado, Mario Reis Álvares-da-Silvainfo:eu-repo/semantics/openAccessLeao, Ari Ben Hur StefaniFerronato, Maria da GraçaKupski, CarlosSchacher, Fernando ComunelloMachado, Denise CantarelliÁlvares-da-Silva, Mario Reis2024-01-19T14:23:02Zoai:seer.ufrgs.br:article/77856Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T14:23:02Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.none.fl_str_mv |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals |
title |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals |
spellingShingle |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals Leao, Ari Ben Hur Stefani Hepcidin HCV interleukin-6 (IL-6) mono-infected Hepatology |
title_short |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals |
title_full |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals |
title_fullStr |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals |
title_full_unstemmed |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals |
title_sort |
Hepcidin serum levels in HCV chronically mono-infected naïve patients, compared to healthy individuals |
author |
Leao, Ari Ben Hur Stefani |
author_facet |
Leao, Ari Ben Hur Stefani Ferronato, Maria da Graça Kupski, Carlos Schacher, Fernando Comunello Machado, Denise Cantarelli Álvares-da-Silva, Mario Reis |
author_role |
author |
author2 |
Ferronato, Maria da Graça Kupski, Carlos Schacher, Fernando Comunello Machado, Denise Cantarelli Álvares-da-Silva, Mario Reis |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Leao, Ari Ben Hur Stefani Ferronato, Maria da Graça Kupski, Carlos Schacher, Fernando Comunello Machado, Denise Cantarelli Álvares-da-Silva, Mario Reis |
dc.subject.por.fl_str_mv |
Hepcidin HCV interleukin-6 (IL-6) mono-infected Hepatology |
topic |
Hepcidin HCV interleukin-6 (IL-6) mono-infected Hepatology |
description |
Introduction: Metabolism of iron is altered in patients infected with chronically Hepatitis C. The aim of this study is to compare compare the hepcidin levels in between individuais chronically infected with HCV and uninfected individuals. The aim of this study is to compare the hepcidin serum levels between individuals chronically infected with HCV and uninfected individuals.Methods: A cross-sectional study evaluating hepcidin serum levels of mono-infected HCV (n=29), naive, non-diabetic, non-cirrhotic and non-obese patients by means of ELISA, compared to uninfected patients (n=9) with the same characteristics. The degree of liver fibrosis, according to the METAVIR scale on liver biopsies, the lipid profile, the resistance insulin level, as calculated on HOMA-IR (homeostatic model assessment for insulin resistance), the interleukin-6 (IL-6) and the ferritin serum levels were also measured.Results: The levels of hepcidin were significantly lower in HCV patients compared to controls (8.4 pg/mL (±4.94) vs. 19.51 pg/mL (±5.51)) with p<0.001. The levels of ferritin and hepcidin did not show any relation. There was no difference between hepcidin levels in relation to viral genotype, viral load, IL-6 and degrees of fibrosis within HCV infected individuals.Conclusion: It is possible that hepatic iron overload in this population is explained by suppressed levels of hepcidin in patients with HCV.Keywords: Hepcidin; HCV; interleukin-6 (IL-6); mono-infected |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-07-19 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article Avaliado por Pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://seer.ufrgs.br/index.php/hcpa/article/view/77856 |
url |
https://seer.ufrgs.br/index.php/hcpa/article/view/77856 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://seer.ufrgs.br/index.php/hcpa/article/view/77856/pdf |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
HCPA/FAMED/UFRGS |
publisher.none.fl_str_mv |
HCPA/FAMED/UFRGS |
dc.source.none.fl_str_mv |
Clinical & Biomedical Research; Vol. 38 No. 2 (2018): Clinical and Biomedical Research Clinical and Biomedical Research; v. 38 n. 2 (2018): Clinical and Biomedical Research 2357-9730 reponame:Clinical and Biomedical Research instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Clinical and Biomedical Research |
collection |
Clinical and Biomedical Research |
repository.name.fl_str_mv |
Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
||cbr@hcpa.edu.br |
_version_ |
1799767054577827840 |